Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study.
Adolescent
Adult
Aged
Antitubercular Agents
/ therapeutic use
Child
Cohort Studies
Female
Humans
Isoniazid
/ therapeutic use
Male
Middle Aged
Morocco
Prospective Studies
Rifampin
/ therapeutic use
Risk Factors
Treatment Failure
Treatment Outcome
Tuberculosis, Multidrug-Resistant
/ drug therapy
World Health Organization
Young Adult
Anti-tuberculosis drugs
Morocco
Resistant tuberculosis
Treatment outcomes
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
11 Apr 2019
11 Apr 2019
Historique:
received:
04
09
2018
accepted:
21
03
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
22
5
2019
Statut:
epublish
Résumé
Drug resistant tuberculosis is a major public health problem in Morocco and worldwide. Treatment outcome of drug resistant tuberculosis is poor and requires a long period of treatment with many toxic and expensive antituberculosis drugs. The aim of this study is to evaluate treatment outcomes of drug resistant tuberculosis and to determine predictors of poor treatment outcomes in a large region of Morocco. It is a multi-centric observational cohort study conducted from January 01, 2014 to January 01, 2016. A questionnaire was established to collect data from clinical charts of patients with confirmed resistant TB. The study was carried out in all the 11 centers located in the Rabat-Salé-Kénitra region of Morocco where drug resistant tuberculosis is treated. Treatment outcomes were reported and the definitions and classifications of these outcomes were defined according to the WHO guidelines. Univariate and multivariate logistic regression were conducted to determine factors associated with poor drug resistant tuberculosis treatment outcomes in Morocco. In our study, 101 patients were treated for drug resistant tuberculosis between January 01, 2014 and January 01, 2016. Patients' age ranged from 9.5 to70 years; 72patients (71.3%) were male and 80 patients (79.2%) were living in urban areas. Thirty two patients were smokers, 74 patients had multidrug-resistant tuberculosis, 25 patients had rifampicin resistance and 2 patients had isoniazid resistance. Treatment outcomes of tuberculosis patients were as follows: 45 patients were cured (44.5%), 9 completed treatment (8.9%), 5 patients died before completing the treatment, 35 patients were lost to follow up (34.6%) and 7 patients had treatment failure. In the multivariate analysis, being a smoker is an independent risk factor for poor treatment outcomes, (p-value = 0.015, OR = 4.355, IC [1.327-14.292]). Treatment success outcomes occurred in more than half of the cases, which is lower than the World Health Organization target of at least a 75% success rate. A significant number of patients abandoned their treatment before its completion. These dropouts are a serious public health hazard that needs to be addressed urgently.
Sections du résumé
BACKGROUND
BACKGROUND
Drug resistant tuberculosis is a major public health problem in Morocco and worldwide. Treatment outcome of drug resistant tuberculosis is poor and requires a long period of treatment with many toxic and expensive antituberculosis drugs. The aim of this study is to evaluate treatment outcomes of drug resistant tuberculosis and to determine predictors of poor treatment outcomes in a large region of Morocco.
METHODS
METHODS
It is a multi-centric observational cohort study conducted from January 01, 2014 to January 01, 2016. A questionnaire was established to collect data from clinical charts of patients with confirmed resistant TB. The study was carried out in all the 11 centers located in the Rabat-Salé-Kénitra region of Morocco where drug resistant tuberculosis is treated. Treatment outcomes were reported and the definitions and classifications of these outcomes were defined according to the WHO guidelines. Univariate and multivariate logistic regression were conducted to determine factors associated with poor drug resistant tuberculosis treatment outcomes in Morocco.
RESULTS
RESULTS
In our study, 101 patients were treated for drug resistant tuberculosis between January 01, 2014 and January 01, 2016. Patients' age ranged from 9.5 to70 years; 72patients (71.3%) were male and 80 patients (79.2%) were living in urban areas. Thirty two patients were smokers, 74 patients had multidrug-resistant tuberculosis, 25 patients had rifampicin resistance and 2 patients had isoniazid resistance. Treatment outcomes of tuberculosis patients were as follows: 45 patients were cured (44.5%), 9 completed treatment (8.9%), 5 patients died before completing the treatment, 35 patients were lost to follow up (34.6%) and 7 patients had treatment failure. In the multivariate analysis, being a smoker is an independent risk factor for poor treatment outcomes, (p-value = 0.015, OR = 4.355, IC [1.327-14.292]).
CONCLUSION
CONCLUSIONS
Treatment success outcomes occurred in more than half of the cases, which is lower than the World Health Organization target of at least a 75% success rate. A significant number of patients abandoned their treatment before its completion. These dropouts are a serious public health hazard that needs to be addressed urgently.
Identifiants
pubmed: 30975090
doi: 10.1186/s12879-019-3931-5
pii: 10.1186/s12879-019-3931-5
pmc: PMC6458640
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Références
N Engl J Med. 2001 Apr 26;344(17):1294-303
pubmed: 11320389
Int J Tuberc Lung Dis. 2003 Feb;7(2):124-31
pubmed: 12588012
Int J Tuberc Lung Dis. 2004 Mar;8(3):361-8
pubmed: 15139476
Lancet. 2005 Jan 22-28;365(9456):318-26
pubmed: 15664227
Int J Tuberc Lung Dis. 2006 Apr;10(4):402-8
pubmed: 16602404
Int J Tuberc Lung Dis. 2006 Apr;10(4):409-14
pubmed: 16602405
Int J Tuberc Lung Dis. 2006 Jun;10(6):649-55
pubmed: 16776452
Lancet. 2006 Dec 16;368(9553):2142-54
pubmed: 17174706
Int J Tuberc Lung Dis. 2007 Mar;11(3):258-62
pubmed: 17352089
Cad Saude Publica. 2007 Jul;23(7):1573-82
pubmed: 17572806
Clin Infect Dis. 2007 Nov 15;45(10):1290-5
pubmed: 17968823
PLoS One. 2007 Nov 07;2(11):e1126
pubmed: 17987113
Clin Infect Dis. 2008 Jan 1;46(1):42-9
pubmed: 18171212
Int J Tuberc Lung Dis. 2008 Oct;12(10):1182-9
pubmed: 18812049
PLoS One. 2009;4(2):e4370
pubmed: 19190774
J Pak Med Assoc. 2009 Oct;59(10):694-8
pubmed: 19813685
Lancet. 2010 May 22;375(9728):1798-807
pubmed: 20488525
Int J Tuberc Lung Dis. 2011 Jun;15(6):838-43
pubmed: 21575308
PLoS One. 2011;6(11):e27610
pubmed: 22110689
Eur Respir J. 2013 Jul;42(1):156-68
pubmed: 23100499
Int J Tuberc Lung Dis. 2013 Mar;17(3):299-307
pubmed: 23211716
Int J Tuberc Lung Dis. 2013 Apr;17(4):520-5
pubmed: 23485386
Thorax. 2015 Dec;70(12):1181-8
pubmed: 26506854
Malays J Med Sci. 2016 Jul;23(4):17-25
pubmed: 27660541
Trop Med Int Health. 2017 Mar;22(3):351-362
pubmed: 27978594
Infect Dis Poverty. 2017 Jan 17;6(1):7
pubmed: 28093078
BMC Infect Dis. 2017 Feb 7;17(1):129
pubmed: 28173763
BMC Infect Dis. 2017 Aug 16;17(1):573
pubmed: 28814276
BMC Infect Dis. 2017 Nov 14;17(1):718
pubmed: 29137626
N Engl J Med. 1995 Oct 5;333(14):907-11
pubmed: 7666876